Suppr超能文献

药物基因组学方法揭示了 x(c)-胱氨酸/谷氨酸反向转运体在神经胶质瘤细胞系的生长和 celastrol 耐药中的作用。

Pharmacogenomic approach reveals a role for the x(c)- cystine/glutamate antiporter in growth and celastrol resistance of glioma cell lines.

机构信息

Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, CA 91766, USA.

出版信息

J Pharmacol Exp Ther. 2010 Mar;332(3):949-58. doi: 10.1124/jpet.109.162248. Epub 2009 Dec 9.

Abstract

The x(c)(-) cystine/glutamate antiporter has been implicated in GSH-based chemoresistance because it mediates cellular uptake of cystine/cysteine for sustenance of intracellular GSH levels. Celastrol, isolated from a Chinese medicinal herb, is a novel heat shock protein 90 (Hsp90) inhibitor with potent anticancer activity against glioma in vitro and in vivo. In search of correlations between growth-inhibitory potency of celastrol in NCI-60 cell lines and microarray expression profiles of most known transporters, we found that expression of SLC7A11, the gene encoding the light chain subunit of x(c)(-), showed a strong negative correlation with celastrol activity. This novel gene-drug correlation was validated. In celastrol-resistant glioma cells that highly expressed SLC7A11, sensitivity to celastrol was consistently increased via treatment with x(c)(-) inhibitors, including glutamate, (S)-4-carboxyphenylglycine, sulfasalazine, and SLC7A11 small interfering RNA. The GSH synthesis inhibitor, buthionine sulfoximine, also increased celastrol sensitivity, whereas the GSH booster, N-acetylcysteine, suppressed its cytotoxicity. Furthermore, the glioma cell lines were dependent on x(c)(-)-mediated cystine uptake for viability, because cystine omission from the culture medium resulted in cell death and treatment with sulfasalazine depleted GSH levels and inhibited their growth. Combined treatment of glioma cells with sulfasalazine and celastrol led to chemosensitization, as suggested by increased celastrol-induced cell cycle arrest, apoptosis, and down-regulation of the Hsp90 client protein, epidermal growth factor receptor. These results indicate that the x(c)(-) transporter provides a useful target for glioma therapy. x(c)(-) inhibitors such as sulfasalazine, a Food and Drug Administration-approved drug, may be effective both as an anticancer drug and as an agent for sensitizing gliomas to celastrol.

摘要

x(c)(-)胱氨酸/谷氨酸反向转运蛋白已被牵连到 GSH 为基础的化学抗性中,因为它介导细胞摄取胱氨酸/半胱氨酸以维持细胞内 GSH 水平。从一种中药中分离出的雷公藤红素是一种新型的热休克蛋白 90(Hsp90)抑制剂,具有强大的体外和体内抗神经胶质瘤活性。在寻找 celastrol 在 NCI-60 细胞系中的生长抑制效力与大多数已知转运蛋白的微阵列表达谱之间的相关性时,我们发现 SLC7A11 的表达,即编码 x(c)(-)的轻链亚基的基因,与 celastrol 的活性呈强烈负相关。这种新的基因-药物相关性得到了验证。在高表达 SLC7A11 的 celastrol 耐药神经胶质瘤细胞中,通过用 x(c)(-)抑制剂(包括谷氨酸、(S)-4-羧基苯甘氨酸、柳氮磺胺吡啶和 SLC7A11 小干扰 RNA)处理,始终可以提高对 celastrol 的敏感性。GSH 合成抑制剂丁硫氨酸亚砜胺也增加了 celastrol 的敏感性,而 GSH 增强剂 N-乙酰半胱氨酸则抑制了其细胞毒性。此外,神经胶质瘤细胞系依赖于 x(c)(-)介导的胱氨酸摄取来维持其生存能力,因为培养基中缺乏胱氨酸会导致细胞死亡,而用柳氮磺胺吡啶处理则会耗尽 GSH 水平并抑制其生长。柳氮磺胺吡啶和 celastrol 联合治疗神经胶质瘤细胞导致化学增敏作用,这表现为 celastrol 诱导的细胞周期停滞、凋亡增加以及 Hsp90 客户蛋白表皮生长因子受体的下调。这些结果表明 x(c)(-)转运蛋白为神经胶质瘤治疗提供了一个有用的靶点。柳氮磺胺吡啶等 x(c)(-)抑制剂,一种获得美国食品和药物管理局批准的药物,可能既是一种有效的抗癌药物,也是一种使神经胶质瘤对 celastrol 敏感的药物。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验